摘要
骨质疏松症是一种常见于中、老年人的以骨组织骨量减少和微观结构退化为特征、致使骨脆性增加并易于发生骨折的疾病。近年来的实验研究及临床流行病学调查提示 ,他汀类 (statins)调血脂药物如洛伐他汀 (lovastatin)等可诱导骨形态发生蛋白 2 (bonemorphogeneticprotein 2 ,BMP 2 )基因表达 ,促进骨合成代谢 ,增加骨密度 ,降低骨质疏松病人发生骨折的危险。他汀类的这一作用具有抗骨质疏松的潜在应用价值 。
Osteoporosis is a common disease in miderate to aged communities. It is characterized by low bone mass and microarchitectural deterioration of bone tissues and that can lead to enhanced bone fragility and a consequent increase in fracture risk. It is recently shown that the statins, such as lovastatin are applied to widely treat hyperlipidemia, enhance new bone formation, increase bone mass density and reduce the risk of osteoporotic fractures. It may induce an increased expression of the bone morphogenetic protein 2 (BMP 2) gene in bone cells. This action of statins may have therapeutic potentials for the treatment of osteoporosis and should be confirmed further by randomized controlled trials.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第4期249-251,共3页
Chinese Journal of New Drugs and Clinical Remedies
